Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and ...
At its Nov. 10 meeting, the Johnson County Planning Board gave preliminary approval for work a property located on Piercetown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback